Deutsch English Français

Contact

EP1091737

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1091737

EP1091737 - Use of 1-(3,3-diphenylpropionyl)-4-benzhydril piperazine in the treatment of pain [Right-click to bookmark this link]
Former [2001/16]	CALCIUM CHANNEL BLOCKERS
	[2004/38]
Status	No opposition filed within time limit Status updated on 21.07.2006 Database last updated on 15.06.2024
Most recent event Tooltip	01.02.2013	Lapse of the patent in a contracting state	published on 06.03.2013 [2013/10]
Applicant(s)	For all designated states Neuromed Technologies, Inc. Suite 301, 2389 Health Sciences Mall Vancouver British Columbia V6T 1Z4 / CA
	[N/P]
Former [2005/37]	For all designated states Neuromed Technologies, Inc. Suite 301, 2389 Health Sciences Mall Vancouver British Columbia V6T 1Z4 / CA
Former [2005/12]	For all designated states Neuromed Technologies, Inc. Suite 301, 2389 Health Sciences Mall Vancouver, British Columbia V6T 1Z4 / CA
Former [2001/16]	For all designated states Neuromed Technologies Inc. Suite 400, 601 West Broadway Vancouver, British Columbia V5Z 4C2 / CA
Inventor(s)	01 / SNUTCH, Terrance, Preston 3963 W. 24th Avenue Vancouver, British Columbia V6S 1M1 / CA
	02 / ZAMPONI, Gerald, Werner 99 Bernard Close N.W. Calgary, Alberta T3K 2H3 / CA
	[2001/16]
Representative(s)	Fisher, Adrian John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2001/16]	Fisher, Adrian John CARPMAELS & RANSFORD 43 Bloomsbury Square London WC1A 2RA / GB
Application number, filing date	99927632.2	30.06.1999
	[2001/16]
	WO1999CA00612
Priority number, date	US19980107037	30.06.1998 Original published format: US 107037
	[2001/16]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO0001375
	Date:	13.01.2000
	Language:	EN
	[2000/02]
	Type:	A2 Application without search report
	No.:	EP1091737
	Date:	18.04.2001
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 13.01.2000 takes the place of the publication of the European patent application.
	[2001/16]
	Type:	B1 Patent specification
	No.:	EP1091737
	Date:	14.09.2005
	Language:	EN
	[2005/37]
Search report(s)	International search report - published on:	EP	31.08.2000
Classification	IPC:	A61K31/495, A61K31/535, A61K31/435, A61P25/04	[2004/38]
	CPC:	C07D295/03 (EP,US); A61K31/535 (KR); A61K31/4468 (EP,US); A61K31/451 (EP,US); A61K31/4515 (EP,US); A61K31/454 (EP,US); (+) A61K31/4545 (EP,US); A61K31/495 (EP,US); A61K31/496 (EP,US); A61K31/498 (EP,US); A61K31/506 (EP,US); A61K31/5375 (EP,US); A61K31/538 (EP,US); A61K31/5415 (EP,US); A61P25/00 (EP); A61P25/04 (EP); A61P25/08 (EP); A61P29/00 (EP); A61P3/14 (EP); A61P43/00 (EP); A61P9/00 (EP); A61P9/10 (EP); A61P9/12 (EP); C07D211/14 (EP,US); C07D211/16 (EP,US); C07D211/46 (EP,US); C07D401/04 (EP,US); C07D401/14 (EP,US); Y02A50/30 (EP,US) (-)
	Former IPC [2001/16]	A61K31/495, A61K31/535, A61K31/435
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2001/16]
Extension states	AL	24.01.2001
	LT	24.01.2001
	LV	24.01.2001
	MK	24.01.2001
	RO	24.01.2001
	SI	24.01.2001
Title	German:	Verwendung von 1-(3,3-diphenylpropionyl)-4-benzhydril piperazine zur Behandlung von Schmerzen	[2004/38]
	English:	Use of 1-(3,3-diphenylpropionyl)-4-benzhydril piperazine in the treatment of pain	[2004/38]
	French:	Usage de la 1-(3,3-diphenylpropionyl)-4-benzhydril piperazine pour le traitement de la douleur	[2004/38]
	Former [2001/16]	CALCIUM-KANAL-BLOCKER
	Former [2001/16]	CALCIUM CHANNEL BLOCKERS
	Former [2001/16]	INHIBITEUR DES CANAUX CALCIQUES
Entry into regional phase	24.01.2001	National basic fee paid
	24.01.2001	Designation fee(s) paid
	24.01.2001	Examination fee paid
Examination procedure	13.01.2000	Request for preliminary examination filed International Preliminary Examining Authority: EP
	24.01.2001	Examination requested [2001/16]
	13.02.2002	Despatch of a communication from the examining division (Time limit: M04)
	18.06.2002	Reply to a communication from the examining division
	29.07.2002	Despatch of a communication from the examining division (Time limit: M04)
	28.11.2002	Reply to a communication from the examining division
	23.06.2003	Date of oral proceedings
	20.08.2003	Minutes of oral proceedings despatched
	18.09.2003	Despatch of communication that the application is refused, reason: substantive examination {1}
	25.03.2004	Despatch of a communication from the examining division (Time limit: M04)
	22.07.2004	Reply to a communication from the examining division
	27.09.2004	Communication of intention to grant the patent
	27.01.2005	Fee for grant paid
	27.01.2005	Fee for publishing/printing paid
Appeal following examination	24.11.2003	Appeal received
	27.01.2004	Statement of grounds filed
	30.04.2004	Interlocutory revision of appeal
Divisional application(s)	EP04076808.7 / EP1466605
Opposition(s)	15.06.2006	No opposition filed within time limit [2006/34]
Fees paid	Renewal fee
	24.01.2001	Renewal fee patent year 03
	07.06.2002	Renewal fee patent year 04
	04.06.2003	Renewal fee patent year 05
	26.04.2004	Renewal fee patent year 06
	06.06.2005	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]ES514167 (FERRER INTERNACIONAL S.A.) [X] 1,3-14,18,19,23 * pages 4-6 * * page 2, line 20 - page 3, line 4 *;
		[X]ES504202 (FERRER INTERNACIONAL S.A.) [X] 1,3-14,18,19,23 * page 4, lines 5-9 * * pages 6-8 *;
		[X]JPH093067 ;
		[X]US3288795 (TSUTOMU IRIKURA, et al) [X] 1-6,9-12,23 * column W * * especially column 1, line 33 *;
		[X]GB1513883 (HOECHST AG) [X] 1,3,5,7,9-12,23 * page 1, line 31 * * page 3, line 17 * * compound 30; page 13; table IV *;
		[X]US4188485 (KUKLA MICHAEL J [US]) [X] 1-6,10,11,13,23 * column A * * column 16; examples 5-8 *;
		[X]EP0187524 (SUNTORY LTD [JP]) [X] 1,3,5-7,9,11,12,23 * page 1, lines 14,15 * * page 16,Table 1,compounds 1,2,4,5,7,10,34 & 35 *;
		[X]US4918073 (RUEGER WOLFGANG [DE], et al) [X] 1-6,9-11,13-16,18-20,22,23 * column W * * especially column 10, line 37-38 *;
		[X]EP0458387 (AKZO NV [NL]) [X] 1-3,5,7,9-13,23 * the whole document *;
		[DX]US5428038 (CHATTERJEE SHYAM S [DE], et al) [DX] 1-3,5,6,9-12,23 * column W *;
		[DX]US5646149 (HELLBERG MARK R [US], et al) [DX] 1-3,6,7,9-11,13,23 * column W *;
		[DX]US5703071 (ITOH NORIIE [JP], et al) [DX] 1-3,5-7,9-11,13,23 * column W *;
		[PX]WO9915129 (BRISTOL MYERS SQUIBB CO [US]) [PX] 1-3,5,6,9-11,23 * page 21, lines 3-12 * * page 141, compounds 115,116 & 117; page 142, compound 118 *;
		[PX]WO9925686 (TEIJIN LTD [JP], et al) [PX] 1-3,5,6,9-11,13,23 * page 7, lines 11-25 * * page 102, compound 901; page 103, compound 907; page 104, compound 923; page 110, compound 987 *;
		[X] - VADODARIA, D.J. ET AL, "Synthesis and central nervous system depressant activity of new piperazine derivatives and related compounds. II", THE JOURNAL OF MEDICINAL CHEMISTRY, (1969), vol. 12, pages 860 - 865, XP000867847 [X] 1-7,9-18,20-23 * the whole document * DOI: http://dx.doi.org/10.1021/jm00305a033
		[X] - CHEMABS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, XP002133053 [X] 1-7,9,10,23 * abstract *
		[ ] - ZIKOLOVA, S. ET AL, "Analogs of 1N-benzhydryl-4N-cinnamylpiperazine (cinnarizine). V. New N1-benzhydryl-N4-substituted piperazines", TR. NAUCHNOIZSLED. KHIM.-FARM. INST., (1984), vol. 14, pages 23 - 28, XP000874822
		[X] - CHEMABS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, XP002133054 [X] 1-7,9,23 * abstract *
		[ ] - ZIKOLOVA, S. ET AL, "Analogs of N1-benzhydryl-N4-cinnamylpiperazine (cinnarizine). II. N1-substtuted-N4-benzhydrylpiperazines", TR. NAUCHNOIZSLED. KHIM.-FARM. INST., (1972), vol. 8, pages 59 - 67, XP000874821
		[DX] - GRANTHAM, C.J. ET AL, "Fluspirilene block of N-type calcium current in NGF-differentiated PC12 cells", BRITISH JOURNAL OF PHARMACOLOGY, (1994), vol. 111, no. 2, pages 483 - 488, XP000874810 [DX] 1-6,9,11,13,23 * the whole document * * especially page 487, righthand column, line 34-49 *
		[DX] - GOULD, R.J. ET AL, "Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, (1983), vol. 80, pages 5122 - 25, XP000867760 [DX] 1-6,9,11,13,23 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.80.16.5122
		[DX] - KING, V.F. ET AL, "Substituted diphenylbutylpiperidines bind to a unique high affinity site on the L-type calcium channel", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1989), vol. 264, no. 10, pages 5633 - 5641, XP000867759 [DX] 1-6,9,11,13,23 * the whole document *
		[X] - ESTEP, K.G. ET AL, "Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels", JOURNAL OF MEICINAL CHEMISTRY, (1995), vol. 38, no. 14, pages 2582 - 2595, XP000867801 [X] 1,3,5,6,9,10,23 * the whole document * DOI: http://dx.doi.org/10.1021/jm00014a011
		[X] - GLAMKOWSKI, E.J. ET AL, "Synthesis of 3-(4-acylaminopiperazin-1-ylalkyl)indoles as potential antihypertensive agents", THE JOURNAL OF MEDICINAL HEMISTRY, (1977), vol. 20, no. 11, pages 1485 - 1489, XP000867800 [X] 1,3,5-7,9,10,23 * the whole document * * especially Table II compound 28 * DOI: http://dx.doi.org/10.1021/jm00221a024
		[X] - OHTAKA, H. ET AL, "Benzylpiperazine derivatives. IV. Syntheses and cerebral vasodilating activities of 1-benzyl-4-diphenylmethylpiperazine derivatives", CHEM. PHARM. BULL., (1987), vol. 35, no. 8, pages 3270 - 3275, XP000867798 [X] 1-5,7,9,10,23 * the whole document * * especially page 3274, line 19-20 *
		[X] - OHTAKA, H. ET AL, "Benzylpiperazine derivatives. V. Quantitative structure-activity relationships of 1-benzyl-4-diphenylmethylpiperazine derivatives for cerebral vasodilating activity", CHEM. PHARM. BULL., (1987), vol. 35, no. 10, pages 4117 - 4123, XP000867799 [X] 1-5,7,9,10,23 * the whole document *
		[X] - MIYANO, S. ET AL, "The synthesis and antilipidperoxidation activity of 4,4-dibutylamines and 4,4-dibutanamides", CHEM. PHARM. BULL., (1990), vol. 38, no. 6, pages 1570 - 1574, XP000867852 [X] 1,3-5,7,9-13,23 * the whole document * * especially page 1570, line 16 *
		[X] - PRASAD, R.J. ET AL, "Potential antihypertensive agents. II. Unsymmetrically 1,4-disubstituted piperazines", JOURNAL OF MEDICINAL CHEMISTRY, (1968), vol. 11, no. 6, pages 1144 - 1150, XP002133052 [X] 1,3-13,23 * abstract * * page 1147, Table IV, compound 59; page 1148, Table V, compound 98 * DOI: http://dx.doi.org/10.1021/jm00312a009
		[X] - TYTGAT, J. ET AL, "Flunarizine inhibits a high threshold inactivating calcium channel (N-type) in isolated hippocampal neurons", BRAIN RESEARCH, (1991), vol. 549, no. 1, pages 112 - 117, XP000874651 [X] 1-5,7,9,23 * the whole document * DOI: http://dx.doi.org/10.1016/0006-8993(91)90606-V
		[X] - COHAN, S.L. ET AL, "Depolarization-induced presynaptic calcium accumulation may occur by an N-type channel that is blocked by flunarizine", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1991), vol. 635, pages 397 - 399, XP000874652 [X] 1-5,7,9,23 * the whole document * DOI: http://dx.doi.org/10.1111/j.1749-6632.1991.tb36508.x
		[X] - UNEYAMA, H. ET AL, "Non-L-type actions of organic Ca2+ channel blockers: Implications for Na+ and N-type Ca2+ channels blockades", CALCIUM ION MODULATORS, SEL. PAP. SATELL. SYMP., (1998), pages 13 - 23, XP000874711 [X] 1-5,7,9,23 * the whole document *
		[X] - DATABASE WPI, 1, Derwent World Patents Index, vol. 97, no. 11, Database accession no. 1997-115265, XP002133055 & JPH093067 A 19970107 (HISAMITSU PHARM CO LTD.) [X] 23 * abstract *
		[X] - LEHMANN, J. ET AL, "Zur struktur und Pharmakologie gamma-lactonverbrückter Diphenylalkylamine", ARCHIV DER PHARMAZIE, (1988), vol. 321, no. 11, pages 807 - 12, XP000874763 [X] 23 * page 808; table 1 * * page 811, column L, line 51; table 6 * DOI: http://dx.doi.org/10.1002/ardp.19883211109
		[X] - DHAINAUT, A. ET AL, "New triazine derivatives as potent modulators of multidrug resistance", THE JOURNAL OF MEDICINAL CHEMISTRY, (1992), vol. 35, no. 13, pages 2481 - 2496, XP000867846 [X] 23 * the whole document * DOI: http://dx.doi.org/10.1021/jm00091a017

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p